No headlines found.
No press releases found.
No news found.
The Fund invests in U.S.-listed equity securities of companies that the Fund's investment sub-advisers expect to benefit from shifts in the regulatory environment that are supportive of free market dynamics. Our proprietary Regulatory Relief Quotient (R2Q) system combines AI-driven regulatory impact analysis with rigorous financial screening to identify companies with the highest deregulation upside potential. These investments may include companies operating in segments of the economy currently burdened by high levels of regulation, such as the healthcare, financial services, and energy sectors, where the Sub-Advisers anticipate regulatory relief. They may also include companies expected to be less adversely affected by increased regulation, such as those in the technology and consumer goods sectors. The Sub-Advisers consider the following to be examples of shifts in the regulatory environment that would be supportive of free market dynamics: removal of government-imposed rules and regulations on specific industries, reduced taxes or tax incentives, licensing reforms, elimination of tariffs, reduction of quotas, reduction of subsidies.
Free Markets ETF trades on the ARCA stock market under the symbol FMKT.
As of January 16, 2026, FMKT stock price declined to $22.73 with 4,755 million shares trading.
FMKT has a market cap of $18.18 million. This is considered a Sub-Micro Cap stock.
FMKT support price is $22.45 and resistance is $23.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FMKT shares will trade within this expected range on the day.
